Applying Real-World Evidence in MS: Reviewing the State of the Art

Slides:

Advertisements

Similar presentations

UK clinical perspective on treatment reviews of multiple sclerosis therapies Alasdair Coles Neurologist, Cambridge, UK.

Advertisements

What Is Meant by "Real-World Data?"

FREEDOMS II TRIAL.

Surgery v Radiation in Prostate Cancer Prasanna Sooriakumaran MD PhD & Peter Wiklund MD PhD.

Applying the New Multiple Sclerosis Guidelines to Clinical Practice

Multiple sclerosis: Oral Therapies and Beyond

Propensity Score Adjustment for Comparative Efficacy Studies of Disease Modifying Agents in Multiple Sclerosis Carrie M. Hersh, DO,1 Claire Hara-Cleaver,

Donald E. Cutlip, MD Beth Israel Deaconess Medical Center

European and US Guidelines

Highlights From the 2017 Annual European MS Meeting

MS Highlights From the 2017 Annual Neurology Meeting

Program Goals Teriflunomide: Pooled Safety Data.

A Paradigm Shift in PAH.

UNDERSTANDING RISK STRATIFICATION IN PAH:

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Immune Reconstitution in MS:

Perspectives on Key MS Data From the Annual Neurology Meeting

What’s the Big Deal About Brain Atrophy and Neurodegeneration in RRMS?

Resistant Hypertension

T-Cell Directed Therapy in MS

Comparing Treatment Alternatives in Ankylosing Spondylitis

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Combination Inhaled Therapy in COPD: The Impact of Recent Data

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Oral vs IV High-Dose Methylprednisolone Are Equally Effective in MS

Are We Closer to Personalized Medicine in MS?

Real-World Safety of NOACs: What Do We Know Today?

Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Breaking Down the CVOTs

What Anticoagulant Registries Are Revealing

Program Goals Disclaimer Overview Assessing Disease Activity.

Targeting BTK Signaling in B-Cell Malignancies

Principles of Comparative Effectiveness in PsA and AS

Examining the Latest Evidence in PAH

Matching Methods & Propensity Scores

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

Treating to Target in MS

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Better Diabetes Control With Novel Basal Insulins

Identifying High-Risk AF Patients

Program Goals Overview Is NEDA a Reasonable Target?

What's New in Therapeutic Options for Moderate to Severe RA?

Expert Perspectives on New Data in Multiple Sclerosis From the 2018 European MS Meeting.

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Clinical Pearls on Hot Topics in MS

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

NEDA 2-Year Endpoint: Not a Predictor of Long-Term Stability?

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Proteasome Inhibitors and Patients

Communicating With Your Patients About Major Depressive Disorder

Real-World Evidence: What Is It and Why Is It so Important In MS?

Analysing RWE for HTA: Challenges, methods and critique

Program Goals Overview Natalizumab Natalizumab: Recent Label Changes.

Secondary Progressive Multiple Sclerosis: What Do We Know and Where Are We Heading?

Program Goals Overview Is NEDA a Reasonable Target?

Oral Therapies in MS.

Novel Therapeutics in MS

Real-World Evidence.

Mitigating Infection Risk With DMT in MS

The ABCs of Therapeutic Strategies in Pregnancy and Multiple Sclerosis

Using Biomarkers in MS: Initiating With the Right Therapy in Clinical Practice.

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.

What's New in PAH?.

Understanding the Role of Disability in MS Management

Shared Decision Making in MS

Selective Immunomodulation in MS

Presentation transcript:

Applying Real-World Evidence in MS: Reviewing the State of the Art

Key MS Registry Studies in Europe, North America, and Globally

Comparison of RCTs vs RWE

Comparison of RCTs vs RWE: Advantages and Limitations

NARCOMS: Patient-Centered Data

Missing Features of RWE

Increase in Published RWE

What Is Driving the Increased Demand for RWE?

Ten Golden Rules for Identifying High-Quality RWE Studies

MSBase: Real-Time Data Capture

Methodologies for Collecting RWE and Examples of Their Application to MS

BigMS

MSDS3D as Interdisciplinary Platform to Manage MS Patients

Eliminating Bias in MS Data

Treatment Switch After Relapse

Baseline Characteristics: Indication Bias

Condense Differences Into a Number: the Probability of Switch to Treatment A or B

Propensity Score Matching in Patients With MS

Examples of Recently Published Real-World Data in MS

Natalizumab vs Fingolimod: Comparative Studies Showing Different Results

MSBase: Treatment Change to Fingolimod or IFN/GA in Patients With Active RRMS

Treatment Change to Fingolimod or IFN/GA in Patients With Active RRMS: Results

MSBase: Comparative Analysis of MS Outcomes

Comparison of 5-Year Treatment Outcomes: Alemtuzumab, Natalizumab, Fingolimod, and IFNβ

PANGAEA: An Evolving Fingolimod Dataset

Survey of Risk Tolerance to MS Therapies

Combining Individual Treatment and Big Data RWE

Predictors of Long-Term Disability Accrual in Relapse-Onset MS

RWE and TOFINGO: Switching From Natalizumab to Fingolimod

Conclusions

Abbreviations

Abbreviations (cont)